Deciphera Pharmaceuticals Financial Statements (DCPH)
|
|
|
|
Report date
|
|
|
09.03.2020 |
09.02.2021 |
08.02.2022 |
07.02.2023 |
07.02.2024 |
|
10.05.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
25.0 |
42.1 |
96.1 |
134.0 |
163.4 |
|
174.9 |
|
Operating Income, bln rub |
|
|
-200.7 |
-271.2 |
-300.1 |
-182.7 |
-211.0 |
|
-206.5 |
|
EBITDA, bln rub |
? |
|
-192.2 |
-264.2 |
-300.1 |
-182.7 |
-208.9 |
|
-203.9 |
|
Net profit, bln rub |
? |
|
-191.5 |
-266.5 |
-296.8 |
-178.9 |
-194.9 |
|
-190.4 |
|
|
OCF, bln rub |
? |
|
-149.3 |
-239.7 |
-240.8 |
-152.9 |
-146.7 |
|
-151.8 |
|
CAPEX, bln rub |
? |
|
4.94 |
5.32 |
5.97 |
0.841 |
0.778 |
|
0.564 |
|
FCF, bln rub |
? |
|
-154.2 |
-245.0 |
-246.8 |
-153.7 |
-147.5 |
|
-152.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
225.7 |
313.1 |
393.3 |
308.0 |
370.6 |
|
374.5 |
|
Cost of production, bln rub |
|
|
0.830 |
0.225 |
2.93 |
8.77 |
3.73 |
|
6.93 |
|
R&D, bln rub |
|
|
157.6 |
199.0 |
257.0 |
187.8 |
234.1 |
|
236.7 |
|
Interest expenses, bln rub |
|
|
0.067 |
0.000 |
0.000 |
4.51 |
0.000 |
|
3.65 |
|
|
Assets, bln rub |
|
|
622.4 |
642.4 |
429.5 |
454.0 |
473.6 |
|
420.9 |
|
Net Assets, bln rub |
? |
|
546.5 |
543.7 |
304.7 |
341.7 |
350.9 |
|
316.1 |
|
Debt, bln rub |
|
|
17.7 |
31.2 |
30.9 |
29.1 |
25.9 |
|
25.0 |
|
Cash, bln rub |
|
|
579.6 |
551.9 |
285.6 |
324.5 |
306.2 |
|
272.5 |
|
Net debt, bln rub |
|
|
-561.9 |
-520.7 |
-254.8 |
-295.4 |
-280.3 |
|
-247.5 |
|
|
Ordinary share price, rub |
|
|
62.2 |
57.1 |
9.77 |
16.4 |
16.1 |
|
11.8 |
|
Number of ordinary shares, mln |
|
|
42.9 |
55.8 |
58.1 |
75.5 |
85.1 |
|
87.4 |
|
|
Market cap, bln rub |
|
|
2 668 |
3 183 |
567 |
1 237 |
1 372 |
|
1 027 |
|
EV, bln rub |
? |
|
2 106 |
2 663 |
313 |
942 |
1 092 |
|
779 |
|
Book value, bln rub |
|
|
546 |
544 |
305 |
342 |
351 |
|
316 |
|
|
EPS, rub |
? |
|
-4.47 |
-4.78 |
-5.11 |
-2.37 |
-2.29 |
|
-2.18 |
|
FCF/share, rub |
|
|
-3.60 |
-4.39 |
-4.25 |
-2.04 |
-1.73 |
|
-1.74 |
|
BV/share, rub |
|
|
12.7 |
9.75 |
5.25 |
4.53 |
4.13 |
|
3.62 |
|
|
EBITDA margin, % |
? |
|
-768.8% |
-627.7% |
-312.1% |
-136.3% |
-127.9% |
|
-116.6% |
|
Net margin, % |
? |
|
-766.0% |
-633.2% |
-308.7% |
-133.5% |
-119.3% |
|
-108.9% |
|
FCF yield, % |
? |
|
-5.78% |
-7.70% |
-43.5% |
-12.4% |
-10.7% |
|
-14.8% |
|
ROE, % |
? |
|
-35.0% |
-49.0% |
-97.4% |
-52.4% |
-55.6% |
|
-60.2% |
|
ROA, % |
? |
|
-30.8% |
-41.5% |
-69.1% |
-39.4% |
-41.2% |
|
-45.2% |
|
|
P/E |
? |
|
-13.9 |
-11.9 |
-1.91 |
-6.92 |
-7.04 |
|
-5.39 |
|
P/FCF |
|
|
-17.3 |
-13.0 |
-2.30 |
-8.05 |
-9.30 |
|
-6.74 |
|
P/S |
? |
|
106.7 |
75.6 |
5.90 |
9.23 |
8.40 |
|
5.87 |
|
P/BV |
? |
|
4.88 |
5.86 |
1.86 |
3.62 |
3.91 |
|
3.25 |
|
EV/EBITDA |
? |
|
-11.0 |
-10.1 |
-1.04 |
-5.16 |
-5.23 |
|
-3.82 |
|
Debt/EBITDA |
|
|
2.92 |
1.97 |
0.85 |
1.62 |
1.34 |
|
1.21 |
|
|
R&D/CAPEX, % |
|
|
3 194% |
3 743% |
4 306% |
22 333% |
30 093% |
|
41 976% |
|
|
CAPEX/Revenue, % |
|
|
19.7% |
12.6% |
6.21% |
0.63% |
0.48% |
|
0.32% |
|
| Deciphera Pharmaceuticals shareholders |
